Research chemicalStimulantResearch chemicalPhenidateDopamine reuptake inhibitor

Isopropylphenidate (IPPH)

Also known as IPPH · IPP · isopropylphenidate

Written by enwyReviewed 4 Aug 20262 sources0 comments

Isopropylphenidate (IPPH) is an isopropyl ester analogue of methylphenidate marketed as a research chemical stimulant. It is reported as a longer-acting, more functional and less compulsive phenidate than ethylphenidate. Human data is essentially anecdotal.

01 Overview

IPPH is a phenidate analogue in which the methyl ester of methylphenidate is replaced by an isopropyl group. Users describe a smoother, longer and more functional stimulant experience with less of the compulsive redosing associated with ethylphenidate.

There are no controlled human studies. Its pharmacology is inferred from methylphenidate and structure-activity relationships within the phenidate class, and its safety and neurotoxic profile are uncharacterised.

02 Mechanism

Inhibits reuptake of dopamine and noradrenaline via transporter blockade, like methylphenidate, with a longer duration attributed to the isopropyl ester.

03 Dosing

Tier	Dose	Route	Notes
Light	5–15 mg	Oral	Anecdotal functional dose.
Common	5–20 mg	Insufflated	Faster onset; increases redosing risk.
Common	15–30 mg	Oral	Longer duration than ethylphenidate; less compulsive.

04 Effects

Effect	Magnitude	Evidence
Focus and wakefulnessSustained attention and energy with a functional, less intoxicating profile.	moderate	Anecdotal
Mild euphoriaModest mood lift, weaker and smoother than ethylphenidate.		Anecdotal
Appetite suppressionReduced hunger during the active period.		Anecdotal

05 Side effects

Effect	Severity	Frequency	Evidence
Cardiovascular strainElevated heart rate and blood pressure typical of phenidates.	Moderate	Common	Unconfirmed
Insomnia and comedownLong duration causes sleep loss followed by fatigue and low mood.	Moderate	Very common	Anecdotal
Compulsive redosingLess compulsive than ethylphenidate but redosing still occurs, especially insufflated.	Moderate	Common	Anecdotal

06 Legal status

Psychoactive Substances Act 2016

Production and supply prohibited. · as of Jan 2026

United States

Not federally scheduled by name

Possible analogue under the Federal Analogue Act. · as of Jan 2026

07 References

Phenidate-class new psychoactive substancesPubMed

New psychoactive substances overviewEUDA (European Union Drugs Agency)

08 Discussion0 comments

Create account

Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.

This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.